🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against increasingly resistant strains of the pathogen, according to scientists.

An International Public Health Issue

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million infections per year. Notably increased rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, escalating drug resistance and the very limited treatment choices at this time.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The global health body has designated it as a "priority pathogen". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Authorization

One new antibiotic, also known as Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, also received approval in the same week. This drug, which is also used to treat UTIs, was demonstrated in studies to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This authorization marks a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Results and Worldwide Availability

As per findings released by a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The trial enrolled over 900 participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in many developing nations.

Clinicians directly involved have shared positive views. Having a one-pill regimen like this is described as a "critical tool" for gonorrhoea control. This is viewed as essential to lessen the impact of the disease for individuals and to prevent the spread of untreatable gonorrhoea worldwide.